Qrem

What Qrem does

Tecnologia Regenerativa Qrem, S.L. is a Barcelona-based medical technology company founded in 2016 that develops and commercializes the Qrem Cytokine platform—a CE-marked Class IIa lab-in-a-box system for producing Autologous Cytokine Rich Serum (ACRS/SARC) from a patient's own blood. The platform combines the QREM DEVICE, a closed automated desktop processor, with KIT QREM CYTOKINE, a single-use sterile disposable kit. The underlying process emulates ex vivo tissue damage through a patented biological protocol—three phases (cell fractionation, platelet and leukocyte activation, cytokine and growth-factor release) executed in eight steps over 36 minutes—yielding a drug-free serum used to treat musculoskeletal and dermatological indications such as osteoarthritis, tendinopathies, soft-tissue injuries, and chronic wounds. The company holds CE marking MDR00040 (Notified Body KIWA Cermet, nº 0476) and AEMPS manufacturer license 7096-PS, and has been commercializing in Europe since 2018.

Qrem operates a razor-and-blade business model: capital-equipment sales of the QREM DEVICE are paired with recurring per-treatment consumable sales of the KIT QREM CYTOKINE. Go-to-market is direct enterprise field sales to medical centers and healthcare professionals, combined with a medical-center referral network surfaced through the company's multilingual website to convert patient interest into clinic demand. The company has secured one disclosed equity round (€1.1M from Inveready in March 2020) and has subsequently financed an active R&D pipeline (>€2.8M cumulative grant budgets across six projects with CDTI, ACCIÓ, MCIN/AEI, and NextGenerationEU partners including Parc Taulí, Hospital Clinic Barcelona, Leitat, and Creatio). Active R&D lines apply predictive analytics and computer vision to osteoarthritis, rheumatoid arthritis, treatment-response prediction, and diabetic foot ulcer prevention.

Operationally Qrem is a micro-cap private entity with 1-10 employees, headquartered in Barcelona, serving European markets only. Public information is limited: no revenue, headcount, installed-base, pricing, or named customer data are disclosed, and ownership is described as founder/independent with no institutional investor cap table publicly available.

Name

Qrem

Legal name

Tecnologia Regenerativa Qrem, S.L.

Website

https://qrem-regenerative.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Tecnologia Regenerativa Qrem is a Barcelona-based medical technology company that sells the CE-marked QREM DEVICE and single-use KIT QREM CYTOKINE—a lab-in-a-box platform producing Autologous Cytokine Rich Serum from patient blood for point-of-care regenerative medicine in musculoskeletal and dermatological indications, sold to healthcare professionals and medical centers in Europe.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Regenerative medicine devices
• Cytokine rich serum
• Lab-in-a-box technology
• Autologous blood therapy
• Musculoskeletal treatment

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (QREM DEVICE): Sale of QREM DEVICE - desktop equipment for obtaining Autologous Cytokine Rich Serum. This is a one-time capital equipment purchase for medical centers and doctors' offices.
2. Consumable Kit Sales (KIT QREM CYTOKINE): Recurring sales of single-use sterile disposable kits. Each patient treatment requires a new kit, creating recurring revenue from the installed base of devices.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Qrem sells a Lab-in-a-box Class IIa CE-marked medical device platform consisting of the QREM DEVICE (desktop processing equipment) and the KIT QREM CYTOKINE (single-use sterile disposable kit) that together extract Autologous Cytokine Rich Serum (ACRS/SARC) from a patient's own blood via a patented 36-minute ex vivo tissue-damage emulation process. The closed, automatic system is sold to doctors and medical centers in Europe for regenerative treatment of musculoskeletal and dermatological pathologies, with the disposable kits generating recurring revenue per patient treatment.

Product overview

Qrem offers the Qrem Cytokine technology platform consisting of two core products: the QREM DEVICE (desktop equipment) and the KIT QREM CYTOKINE (single-use sterile disposable kit). Together they enable the extraction and processing of the patient's own blood to produce Autologous Cytokine Rich Serum (ACRS), also known as Suero Autólogo Rico en Citoquinas (SARC). This lab-in-a-box technology is used for regenerative medicine treatments in musculoskeletal and dermatological clinical specialties.

Differentiator

Problem solved

Functional benefit

Products and services

• QREM DEVICE Desktop medical device that automatically processes the KIT QREM CYTOKINE through an 8-step, 36-minute cycle to obtain Autologous Cytokine Rich Serum (ACRS/SARC). A closed, automatic Class IIa CE-marked non-implantable device sold to doctors and medical centers for in-office regenerative medicine treatments.
• KIT QREM CYTOKINE Single-use sterile disposable kit filled with the patient's blood and processed inside the QREM DEVICE to produce ACRS/SARC. The closed system can be installed and operated in any doctor's office without special infrastructure or trained personnel, and each kit yields one patient treatment, creating recurring per-procedure revenue.
• Qrem Cytokine Technology Platform End-to-end offering combining the QREM DEVICE and KIT QREM CYTOKINE as a turnkey Lab-in-a-box service for medical professionals to deliver autologous regenerative therapy in their consulting rooms without specialized infrastructure. Sold as a combined solution enabling ACRS/SARC treatment during a first patient visit.

Quantifiable outcome

• Process completed in 36 minutes, enabling ACRS administration during a first visit

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Parc TaulícoreStrategic or Co-development PartnerResearch institution collaborating on SERHA project studying patterns of cellular and molecular senescence in rheumatoid arthritis and response to autologous serum enriched in cytokines.
• Leitat Technology CentercoreStrategic or Co-development PartnerTechnology center collaborating on SERHA project for rheumatoid arthritis research and development of regenerative medicine solutions.
• Clinic BarcelonacoreStrategic or Co-development PartnerMajor university hospital in Barcelona collaborating on regenerative medicine research and development projects.
• CreatiocoreStrategic or Co-development PartnerResearch center atUniversitat Politècnica de Catalunya collaborating on cell therapy and regenerative medicine development.
• CataloniaBio & HealthTechminorStrategic or Co-development PartnerBiomedicine and health technology cluster in Catalonia supporting innovation and collaboration in the healthcare sector.
• Kiwa CermetcoreTechnology or IntegrationNotified Body (nº 0476) that granted CE marking MDR00040 for QREM DEVICE and KIT QREM CYTOKINE Class IIa medical devices.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Regen Lab: Swiss medical device company producing closed-system kits for preparing autologous PRP and cell therapies at the point of care. Directly comparable to Qrem's lab-in-a-box ACRS platform in target customers (clinics), clinical applications (MSK, aesthetic), and business model (capital device + consumable kits).
• Emcyte Corporation: US-based manufacturer of PRP and concentrated bone marrow aspirate systems (e.g., PurePRP, GenesisCS) for point-of-care regenerative treatments. Closely comparable in offering point-of-care autologous blood-processing devices to MSK and aesthetics practitioners.
• Isto Biologics: Orthobiologics company offering autologous platelet and cell-based therapies as well as bone graft substitutes for musculoskeletal applications. Comparable target market (orthopedic surgeons, sports medicine, pain management) and overlapping regenerative-medicine value proposition.
• Royal Biologics: Regenerative medicine company providing autologous platelet-rich fibrin and stem-cell-based therapies for orthopedic and wound-care applications. Closely comparable as a niche player in autologous point-of-care regenerative devices competing for similar clinic customers.
• GID BIO: Developer of point-of-care autologous stromal vascular fraction (SVF) and cell-processing systems for regenerative medicine clinics. Directly comparable in selling closed-system devices that process patient tissue at the point of care for orthopedic and aesthetic applications.
• Geistlich Pharma: Swiss-based orthobiologics and regenerative medicine company best known for dental bone substitutes but with a growing presence in cartilage regeneration and autologous therapies. Comparable as a specialized regenerative-medicics supplier to MSK and dental specialists.
• ThermoGenesis Holdings: US-listed company (formerly Cesca Therapeutics) developing automated autologous cell-processing systems for point-of-care regenerative therapies. Comparable in providing closed automated cell/blood-processing devices that compete with Qrem's lab-in-a-box value proposition.

Broad incumbents

• Arthrex: Large orthopedic medical device incumbent offering the Angel PRP/concentrated BMAC system alongside a full orthopedic surgical portfolio. Comparable as an established competitor in autologous regenerative medicine for MSK pathologies, but operates much more broadly than Qrem's narrow ACRS focus.
• Terumo BCT: Global medical device division of Terumo supplying apheresis, cell collection, and cell-processing systems used in cell therapy manufacturing and blood component preparation. Comparable as a broader incumbent in automated closed-system blood/cell processing, though focused on larger hospital/cell-therapy manufacturers rather than point-of-care clinics.

Others

• BioLife Solutions: Supplier of biopreservation media and cell-processing consumables to the cell therapy and regenerative medicine industry. Comparable as an enabling ecosystem participant in the autologous cell/biologic handling workflow that Qrem's lab-in-a-box platform also serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/tr_qrem
• YouTubeyoutube.com/channel/UCzldb2DuZ_JDbfTmGpBxsUQ
• LinkedInlinkedin.com/company/tecnologia-regenerativa-qrem-s.l.
• Instagraminstagram.com/qrem_regenerative

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qrem